Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1953 Apr;97(4):573-89.
doi: 10.1084/jem.97.4.573.

The inactivation of complement and its components by plasmin

The inactivation of complement and its components by plasmin

L PILLEMER et al. J Exp Med. 1953 Apr.

Abstract

Human complement is inactivated by plasmin, the proteolytic enzyme of plasma or serum active at or near neutrality. The addition of streptokinase to human serum, which converts plasminogen to plasmin, also causes the inactivation of complement components C'2 and C'4 and varying amounts of C'1. C'3 is the most resistant to inactivation by plasmin. Chloroform-activated human plasmin and bovine plasmin also destroy these components of complement, but are less effective than the streptokinase-activated enzyme. The inactivation of complement by the addition of streptokinase to human serum is inhibited by high hydrogen ion concentrations, low temperature, and elevated ionic strength. The inactivation of the components of complement in various fractions of serum is influenced by the available plasminogen and the content of plasmin inhibitors in these fractions. Certain similarities are pointed out between the components of complement and the factors in the plasmin system and between the inactivation of the components of complement by antigen-antibody reactions, by specific agents, and by plasmin. The possible significance of these relationships in immune hemolysis and complement fixation, and the possible role of the plasmin system in the instability of complement and the development of anticomplementary properties in serum are discussed.

PubMed Disclaimer

References

    1. Proc Soc Exp Biol Med. 1950 Apr;73(4):559-62 - PubMed
    1. J Exp Med. 1945 May 1;81(5):449-68 - PubMed
    1. J Exp Med. 1948 Mar 1;87(3):199-209 - PubMed
    1. J Immunol. 1952 Jan;68(1):11-8 - PubMed
    1. Science. 1946 Nov 15;104(2707):461-2 - PubMed